NCT03959085 2026-05-05Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyChildren's Oncology GroupPhase 3 Recruiting5,951 enrolled